Richtlinien zu Diagnostik und Therapie von Erkrankungen sollten \u201dEvidenz-basiert\u201d sein. Da\u00df man Evidenz unterschiedlich bewerten oder klinische Studien f\u00fcr mehr oder weniger mangelhaft halten kann, zeigt ein Vergleich der neuen therapeutischen Richtlinien f\u00fcr den Diabetes mellitus Typ 2 (DM2). Erstens gibt es die Nationale Versorgungs-Leitlinie (NL), die von der Bundes\u00e4rztekammer, der Arzneimittelkommission der deutschen \u00c4rzteschaft […]<\/p>\n","protected":false},"excerpt":{"rendered":"
Richtlinien zu Diagnostik und Therapie von Erkrankungen sollten \u201dEvidenz-basiert\u201d sein. Da\u00df man Evidenz unterschiedlich bewerten oder klinische Studien f\u00fcr mehr oder weniger mangelhaft halten kann, zeigt ein Vergleich der neuen therapeutischen Richtlinien f\u00fcr den Diabetes mellitus Typ 2 (DM2). Erstens gibt es die Nationale Versorgungs-Leitlinie (NL), die von der Bundes\u00e4rztekammer, der Arzneimittelkommission der deutschen \u00c4rzteschaft […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[3886,954,366,1279,1280,1281,338,339,1282,1558,367,1283,340,341,4163,342,343,81,80,82,949,160,2807,933,4718,818,1011,2973,1012,5116,1013,362,1538,5513,448,5924,5926,852,6244,6469,1039,345,1014,6979,6980,6981,6984,6985,6986],"class_list":["post-40422","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acarbose","tag-ace-hemmer","tag-akdae","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-antihypertensiva","tag-arzneimittelkommission-der-deutschen-aerzteschaft","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-blutdruck","tag-diabetes-mellitus-typ-2","tag-diabetes-diaet","tag-diabetische-nephropathie","tag-disease-management-programm","tag-ernaehrung","tag-glibenclamid","tag-glimepirid","tag-glipizid","tag-glitazone","tag-glyburid","tag-hypertonie","tag-insulin","tag-koordinierungsausschuss","tag-metformin","tag-nateglinid","tag-nationale-versorgungs-leitlinie","tag-orale-antidiabetika","tag-pioglitazon","tag-repaglinid","tag-rosiglitazon","tag-sartane","tag-sulfonylharnstoffe","tag-ukpds-studie-24","tag-ukpds-studie-33","tag-ukpds-studie-34","tag-ukpds-studie-38","tag-ukpds-studie-39","tag-ukpds-studie-40"],"yoast_head":"\n